Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
Clinical trial NCT00546793 · COMPLETED
Trial details
- NCT number
- NCT00546793
- Sponsor
- Gilead Sciences
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2008-01-01
- Primary completion
- 2013-03-01
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.